OSTX OS Therapies Inc.: רווח למניה לשנה מתגלגלת

OS Therapies Incorporated (OSTX) attracts leading oncology scientists by creating a flexible drug development environment free from corporate pressure. This chart of EPS TTM price action demonstrates profit dynamics, which currently stand at -41.80. The company enjoys immense respect from physicians for its vaccine development, maintaining its status as a bold innovator. The business focuses on combating rare bone tumors, saving children and young adults.
פילוחי מדדים פיננסיים ומדדי שוק עבור OS Therapies Incorporated (OSTX)

OS Therapies Incorporated (OSTX) minimizes biotechnological risks through the diversification of clinical trials for targeted drugs against solid tumors and licensing agreements. The measurement of annual EPS TTM growth reflects the rolling earnings per share trend, allowing investors to assess the business's actual ability to generate cash flow, while a sharp spike in this trajectory may signal the risk of overpaying for the asset.